![]() NTUS shares were down -4.8% at $17.69 per share in midday trading today. Natus will continue to withhold its 2020 financial guidance at this time due to the uncertainties caused by the pandemic. We see our customers adapting to the COVID environment with elective procedures resuming, which we believe will result in increased capital spending, improving our business over the remainder of 2020.” We expect newborn care to remain closer to historical levels. “Looking ahead to the third quarter, we expect neuro and hearing & balance revenues to remain below pre-pandemic levels, but to improve compared to the second quarter. To read this article on click here.“As expected, we saw significant impact from COVID-19 during the second quarter, with revenue declining 32.5% compared to the second quarter of 2019,” Natus president & CEO Jonathan Kennedy said in a news release. JOHNSON & JOHNS (JNJ): Free Stock Analysis Report NATUS MEDICAL (BABY): Free Stock Analysis ReportĪNGIODYNAMICS (ANGO): Free Stock Analysis ReportĪBIOMED INC (ABMD): Free Stock Analysis Report Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Other stocks with a better rank are ABIOMED (ABMD) and AngioDynamics (ANGO). We also believe that innovation in the product pipeline will help Natus Medical fight off competition from the likes of Johnson & Johnson (JNJ), Astro-Med and NeuroMetrix.Ĭurrently, Natus Medical has a Zacks Rank #3 (Hold). Revenue guidance was also revised up to a range of $353.8 to $355.8 million (previous guidance was $347.5 to $352.5 million). Natus Medical also raised its non-GAAP earnings guidance for full-year 2014, which is now expected in the band of $1.23 to $1.25 (up from $1.20 to $1.23). The mid-point of the guided range is in line with the Zacks Consensus Estimate. Meanwhile, non-GAAP earnings are forecasted in the range of 37 cents to 39 cents. Natus Medical expects revenues in the range of $92 million to $94 million for the fourth quarter. Based on the strong product line and impressive third-quarter results, the company provided an optimistic fourth-quarter outlook. Natus Medical’s frequent new product launches and an innovative pipeline for both the newborn care and neurology platforms is a key growth catalyst. We believe that the new Nicview offering will gain significant traction among hospital nurseries, which will drive top-line growth in the long run. Nicview offers a complete set of IP cameras, mobile viewing links and a service program that enables video streaming. Using Nicview’s technology, any member of the family with a valid password can view the newborn at NICU through personal computers or mobile devices. ![]() The company recently acquired technology company, Nicview, which pioneered video streaming of babies who are under treatment in the neonatal intensive care unit (NICU). Natus Medical Inc (BABY) is presently focusing on enhancing its offerings for the newborn care market.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |